Socio-demographic and drug use factors associated with HIV-1 recombinants and dual infections in Northern Thai drug users: Associations of risk with genetic complexity by Kijak, G. H. et al.
University of Nebraska - Lincoln 
DigitalCommons@University of Nebraska - Lincoln 
US Army Research U.S. Department of Defense 
2010 
Socio-demographic and drug use factors associated with HIV-1 
recombinants and dual infections in Northern Thai drug users: 
Associations of risk with genetic complexity 
G. H. Kijak 
US Military HIV Research Program, drkijak@gmail.com 
C. Beyrer 
Johns Hopkins Bloomberg School of Public Health 
S. Tovanabutra 
US Military HIV Research Program 
T. Sripaipan 
Johns Hopkins Bloomberg School of Public Health 
V. Suriyanon 
Research Institute for Health Sciences 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.unl.edu/usarmyresearch 
 Part of the Operations Research, Systems Engineering and Industrial Engineering Commons 
Kijak, G. H.; Beyrer, C.; Tovanabutra, S.; Sripaipan, T.; Suriyanon, V.; Moqueet, N.; Sanders-Buell, E.; 
Saokhieo, P.; Timpan, U.; Jittiwutikarn, J.; Robb, M. L.; Birx, D. L.; Celentano, D. D.; and McCutchan, F. E., 
"Socio-demographic and drug use factors associated with HIV-1 recombinants and dual infections in 
Northern Thai drug users: Associations of risk with genetic complexity" (2010). US Army Research. 133. 
https://digitalcommons.unl.edu/usarmyresearch/133 
This Article is brought to you for free and open access by the U.S. Department of Defense at 
DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in US Army Research by an 
authorized administrator of DigitalCommons@University of Nebraska - Lincoln. 
Authors 
G. H. Kijak, C. Beyrer, S. Tovanabutra, T. Sripaipan, V. Suriyanon, N. Moqueet, E. Sanders-Buell, P. Saokhieo, 
U. Timpan, J. Jittiwutikarn, M. L. Robb, D. L. Birx, D. D. Celentano, and F. E. McCutchan 
This article is available at DigitalCommons@University of Nebraska - Lincoln: https://digitalcommons.unl.edu/
usarmyresearch/133 
Please cite this article in press as: Kijak, G.H., et al., Socio-demographic and drug use factors associated with HIV-1 recombi-
nants and dual infections in Northern Thai drug users: Associations of risk with genetic complexity. Drug Alcohol Depend. (2011),
doi:10.1016/j.drugalcdep.2010.11.013
ARTICLE IN PRESSGModelDAD-3966; No.of Pages7
Drug and Alcohol Dependence xxx (2010) xxx–xxx
Contents lists available at ScienceDirect
Drug and Alcohol Dependence
journa l homepage: www.e lsev ier .com/ locate /drugalcdep
Full length article
Socio-demographic and drug use factors associated with HIV-1 recombinants
and dual infections in Northern Thai drug users: Associations of risk with
genetic complexity
G.H. Kijaka,∗, C. Beyrerb, S. Tovanabutraa, T. Sripaipanb, V. Suriyanonc, N. Moqueeta,
E. Sanders-Buell a, P. Saokhieoc, U. Timpanc, J. Jittiwutikarnd, M.L. Robba, D.L. Birxe,1,
D.D. Celentanob, F.E. McCutchana,2
a US Military HIV Research Program, Henry M Jackson Foundation, 1600 East Gude Drive, Rockville, MD 20850, USA
b Johns Hopkins Bloomberg School of Public Health, 615N. Wolfe St., Suite E 7152, Baltimore, MD, USA
c Research Institute for Health Sciences, PO Box 80 CMU 110, Intavaroros Road, Muang, Chiang Mai 50202, Thailand
d Northern Drug Treatment Center, PO Box 6 Mae Rim, Mae Rim District, Chiang Mai 50180, Thailand
e US Military HIV Research Program, Division of Retrovirology, Walter Reed Army Institute of Research,
Henry M Jackson Foundation, 1600 East Gude Drive, Rockville, MD, USA
a r t i c l e i n f o
Article history:
Received 27 November 2009
Received in revised form 29 October 2010
Accepted 8 November 2010
Available online xxx
Keywords:
Injection drug use
HIV/AIDS
Recombination
Dual infection
Molecular epidemiology
Injecting risk
Thailand
Multi-region hybridization assay
a b s t r a c t
Background:Dual infectionwith diverseHIV strains can foster the emergence of recombinants. The result-
ing increase in viral genetic diversity is a major challenge for vaccine development HIV treatment. In this
study we aim to investigate the socio demographic factors associated with an increasing level of genetic
diversity among HIV strains in a population of drug-users in Northern Thailand.
Methods: From1999 through 2000, 2231 volunteerswere enrolled in theOpiate-Users Research in Chiang
Mai, Thailand. HIV subtype analysis was conducted among those HIV-1 seropositive (n=347) using a
multi-region hybridization assay. Social and demographic variables were assessed using a structured
questionnaire.
Results: Overall, 336/347 (96.8%) of the samples could be typed. 81.8% were CRF01 AE, 3.9% were sub-
type B, 9.2% were recombinants (mostly between CRF01 AE and B) and 5.1% were dual infections. Dual
infections were more frequent among those with a lower education level (AOR: 5.2; 95% CI 1.4–20.3),
those who have initiated injecting in the last 3 years (AOR: 3.9; 95% CI 1.1–14.6), and those reporting
frequent needle sharing in the last 3 months (AOR: 7.0; 95% CI 1.5–34.1). Both recombinant strains and
dual infection were more frequent among those reporting frequent needle sharing in the last 3 months
(AOR: 5.3; 95% CI 1.6–17.1).
Conclusion: To limit the expanding complexity of HIV-1 strains, early intervention should be aimed at
reduction in needle sharing, especially among new intravenous drug users.
© 2010 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
Human immunodeficiency virus type 1 (HIV-1) is characterized
by extensive and expanding genetic diversity. To date, 9 subtypes
within the groupM radiation have been described, andmanymore
inter-subtype recombinants have been reported (Kuiken et al.,
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2009). Recombinant strains are believed to emerge after dual infec-
tions within multiply-exposed individuals (Ramos et al., 2002;
Taylor et al., 2008). While some of these recombinant strains have
been retrieved from only one patient (“unique recombinant forms”
or URFs), other recombinants have spread into populations (“cir-
culating recombinant forms” or CRFs) (Taylor et al., 2008). By
combining pre-existing beneficial mutations, recombination can
accelerate the escape from host immune responses and recent
studies suggest that HIV-1 envelope has adapted to evade such
responses at population levels (Bunnik et al., 2010). For this rea-
son, HIV dual infection and recombination pose major challenges
to vaccine design and can hinder the evaluation of the success of
efficacy trials. Dual infection has been associated with accelerated
disease progression (reviewed by Smith et al., 2005) and increas-
0376-8716/$ – see front matter © 2010 Elsevier Ireland Ltd. All rights reserved.
doi:10.1016/j.drugalcdep.2010.11.013
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ing genetic diversity has also been linked to anti-retroviral drug
resistance, suggesting that diversity may also play roles in HIV
therapeutic outcomes (Djoko et al., 2010). Identifying individuals
and sub-groups of populations where dual infections are more fre-
quent and recombinant forms are more likely to arise could help
in the design and targeting of preventive interventions aimed at
diminishing HIV-1 genetic complexity. Little work has been done
on the injection drug use behaviors and practices that might con-
tribute to multiple exposure and dual infection among injecting
and non-injecting drug users.
The molecular epidemiology of HIV-1 in Thailand has substan-
tially changed over the past two decades. From the late 1980s
until the mid 1990s, HIV-1 strains were segregated by risk group,
as subtype B predominated among injecting drug users (IDUs),
while CRF01 AE was the major form circulating among those
with heterosexual exposure (Subbarao et al., 1998). A change
in the proportions of clades was seen in the mid 1990s, when
CRF01 AE overtook subtype B among IDUs, while still constituting
the major clade being transmitted through heterosexual contact
(Tovanabutra et al., 2004; Vanichseni et al., 2001). CRF01 AE was
also the predominant clade identified among male sex workers in
Northern Thailand (Beyrer et al., 1997). Subsequently, our group
reported on the emergence of novel recombinant HIV-1 strains
between CRF01 AE and subtype B, which were thought to have
emerged in successive rounds of dual infection and transmission
among multiply-exposed individuals. By the early 2000s, more
than half of new infections among IDUs in Northern Thailand were
caused by B/CRF01 AE URFs (Tovanabutra et al., 2004), marking a
substantial increase in genetic complexity. Moreover, B/CRF01 AE
recombinants were also found in contemporary samples from the
general population, and two new CRFs, CRF15 01B (Tovanabutra
et al., 2001) and CRF34 01B (Tovanabutra et al., 2007), were found
in multiple individuals, some with heterosexual risk factors and
some others with IDU risk factors and, presumably, some individu-
als with dual risks for HIV acquisition and transmission. As the Thai
epidemic matured, the emergence of these subtypes confirmed
increasing genetic diversity, and also established the bridging of
IDU and general population HIV-1 variants at molecular levels.
Non-injecting drug users in Thailand predominantly use variants
of methamphetamine (Ya Ba, or “crazy medicine”, in Thai), which
is generally smoked, not injected. Their demographic and HIV risks
vary markedly from IDU and we have previously reported on their
lower HIV rates in this cohort (Beyrer et al., 2004).
The Northern region of Thailand, including provinces adjacent
to the Golden Triangle in the border with Burma (Myanmar) and
Laos, has borne the brunt of the Thai HIV-1 epidemic since its onset.
By 2003, this region, that represented only 8% of the country’s total
population,washometomore than25%of theAIDScases (Deewong
and Jitnumshap, 2003). The Northern Thai epidemic was marked
by both sexual and IDU components, and by the region’s exten-
sive commercial sex industry—largely employing sexworkers from
impoverished Burma, and by high rates of methamphetamine use
among adolescents and young adults.
The objective of this study was to evaluate the HIV-1 genetic
diversity among sero-positive drug users, both injecting and non-
injecting, seeking detoxification at the Chiang Mai Drug Treatment
Center (CMDTC), Mae Rim, Thailand, which serves 17 provinces
in the northern region. Behavioral and social/demographic vari-
ables anddrugusepracticeswere investigated for associationswith
increasing complexity of HIV-1 strains.
2. Methods
2.1. Population under study
The Opiate-Users Research (OUR) Studywas conducted among 2231 volunteers
seeking detoxification at the ChiangMai Drug Treatment Center (CMDTC), Mae Rim,
Thailand. The first phase of the study (February 1999–January 2000) included volun-
teers admitted for opioid or methamphetamine dependence, and the second phase
of the study (February 2000–December 2000) included only IDUs admitted for drug
dependence. Inclusion criteria included being 13 years of age or older, provision
of informed consent, admission for substance use dependence, agreement to sub-
mit to pre- and post-test HIV counseling and venipuncture for HIV serology and
HIV subtyping, and completion of a behavioral questionnaire, which was adminis-
tered in a confidential face-to-face interview. Detailed methods and findings from
this study have been previously published elsewhere (Cheng et al., 2006; Razak
et al., 2003). The study was approved by the institutional review boards of the
Royal Thai Ministry of Public Health, Research Institute of Health Sciences, Chi-
ang Mai University and the Johns Hopkins University. Since persons aged 13–18
were admitted to the drug treatment centers with parental or guardian consent,
they were deemed eligible for recruitment into this study if parental consent and
individual adolescent assent were obtained and this was approved by all relevant
IRBs.
2.2. HIV-1 serology
Specimenswere tested for HIV antibodies by ELISA using licensed commercially
available reagents (Vironostica HIV Uni-form II plus 0; Organon Teknika). Reactive
ELISA specimens were tested with the gel-particle agglutination (GPA) test for anti-
bodies to HIV (Serodia-HIV; Fujirebio, Japan). Specimens testing positive in both
antibody testswere consideredHIV positive. GPA-nonreactive specimenswere con-
firmedbyWesternblot analysis using licensed commercially available reagents (HIV
Blot 2.2; Genelabs Diagnostics, Singapore).
2.3. HIV-1 subtyping
Viral RNAwas extracted from serum samples by robotic extraction (MagnaPure,
Roche Diagnostics). The presence of subtypes B, C, and CRF01 AE, and recombinants
and dual infections combining these strains was evaluated using a multi-region
hybridization assay (MHAbce v2) as previously published (Tovanabutra et al., 2007).
Briefly, after PCR-amplification 8 regions throughout the HIV genome (p17 in gag;
protease, reverse transcriptase, and integrase in pol; the first exon of tat; gp120
and gp41 in env; and nef) with universal primers, their subtype was assessed in
real-time PCRs with respective fluorescent TaqMan probes specific for subtypes B,
C and CRF01 AE. Samples with concordant patterns of probe reactivity through-
out the genome were assigned to the corresponding subtype or CRF, while those
samples showing discordant patterns of probe reactivity were considered inter-
subtype recombinants. Patients with samples exhibiting dual-probe reactivity in
the same genome region were considered as dually infected after verification by
cloning and real-time PCR subtyping of at least 20 clones per sample. Only sam-
ples showing probe reactivity in 4 genome regions or more were considered as
typed.
2.4. Statistical methods
HIV-1 infections were classified into 9 different genotypes: subtype B;
subtype C; CRF01 AE; B/CRF01 AE Recombinant; C/CRF01 AE Recombinant; B/C
Recombinant; B/CRF01 AE Dual; C/CRF01 AE Dual; and B/C Dual. Single infec-
tions were defined as the presence of subtypes B, C, or CRF01 AE, or any
of the recombinant genotypes. Dual infections were defined as the pres-
ence of B/CRF01 AE Dual; C/CRF01 AE Dual; and B/C Dual genotypes following
the accepted classification used elsewhere (Arroyo et al., 2005, 2006, 2009;
Herbinger et al., 2006; Hoelscher et al., 2002; Kijak et al., 2007; Saathoff et al.,
2010).
Exposure variables of interest included: socio-demographics (age, ethnicity,
education, occupation, marital status, and residence); incarceration; injection risks
and practices (time since first injection, frequency of injection, needle and injection
equipment sharing); and sexual risks (lifetime number of sex partners, sex with a
female sexworker, sexwith anotherman formale IDU, and STD diagnoses and prior
history of STD).
Differences in the distribution of dual HIV infection across variables of inter-
est were assessed using the chi-square test and Fisher’s Exact test (if expected
cell count was less than 5) for categorical variables, and the Wilcoxon rank sum
test for continuous variables. Continuous variables were also categorized based on
quartiles and further analyzed as categorical variables. Logistic regression was used
to obtain crude odds ratios and 95% confidence intervals. Due to small numbers
observed in some genotypes, multivariatemodels were not built; however, because
age and education level appeared to differ across genotypes, as well as be closely
related to other variables of interest, logistic regression was used to obtain age-
adjusted and education-adjusted odds ratios and 95% confidence intervals for those
variables with a significance level ≤0.10 in the crude analysis. All statistical anal-
yses were conducted using SAS for Windows version 9.1 (SAS Institute Inc, Cary,
NC).
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Table 1
Socio-demographic characteristics and HIV sero-prevalence among admissions to the Northern Drug Dependence Treatment Center, Thailand, 1999–2000, for the overall
OUR prevalence study population (N=2231).
Characteristic Total Male Female
No. tested No. HIV
positive (%)
OR (95% CI)* No. tested No. HIV
positive (%)
OR (95% CI)* No. tested No. HIV
positive (%)
OR (95% CI)*
Total 2231 347 (15.6) 2005 324 (16.2) 226 23 (10.2)
Ethnicity
Ethnic
minority
993 117 (11.8) 1.0 840 104 (12.4) 1.0 153 13 (8.5) 1.0
Thai 1238 230 (18.6) 1.7 (1.3–2.2) 1165 220 (18.9) 1.7 (1.3–2.1) 73 10 (13.7) 1.7 (0.7–4.1)
Age
15–23 years 788 89 (11.3) 1.0 (0.7–1.3) 717 82 (11.4) 1.0 (0.7–1.3) 71 7 (9.9) 1.0 (0.4–2.9)
24–29 368 99 (26.9) 2.8 (2.0–3.9) 345 95 (27.5) 2.8 (2.0–3.9) 23 4 (17.4) 2.0 (0.6–7.2)
30–34 323 72 (22.3) 2.2 (1.6–3.1) 298 70 (23.5) 2.3 (1.6–3.2) 25 2 (8.0) 0.8 (0.2–4.1)
35+ 752 87 (11.6) 1.0 645 77 (11.9) 1.0 107 10 (9.4) 1.0
Marital status
Married 930 88 (9.5) 1.0 804 78 (9.7) 1.0 126 10 (7.9) 1.0
Never
married
950 163 (17.2) 2.0 (1.5–2.6) 908 161 (17.7) 2.0 (1.5–2.7) 42 2 (4.8) 0.6 (0.1–2.8)
Separated/
divorced/
widowed
351 96 (27.3) 3.6 (2.6–5.0) 293 85 (29.0) 3.8 (2.7–5.4) 58 11 (19.0) 2.7 (1.1–6.8)
Education level
Primary
school or
less
1011 174 (17.2) 1.3 (1.0–1.6) 942 165 (17.5) 1.2 (0.95–1.5) 69 9 (13.0) 1.5 (0.6–3.7)
Secondary
school or
more
1220 173 (14.2) 1.0 1063 159 (15.0) 1.0 157 14 (8.9) 1.0
Occupation
Student 243 6 (2.5) 1.0 219 5 (2.3) 1.0 24 1 (4.2) 1.0
Farmer 865 92 (10.6) 4.7 (2.0–10.9) 779 88 (11.3) 5.5 (2.1–3.6) 86 4 (4.7) 1.1 (0.1–10.5)
Unemployed 407 63 (15.5) 7.2 (3.1–17.0) 366 56 (15.3) 7.7 (3.1–19.6) 41 7 (17.1) 4.7 (0.6–41.1)
Laborer 392 117 (29.9) 16.8 (7.3–38.8) 339 109 (32.2) 20.3 (8.1–50.7) 53 8 (15.1) 4.1 (0.5–34.7)
Trader 133 33 (24.8) 13.0 (5.23–32.0) 123 31 (25.2) 14.4 (5.4–38.3) 10 2 (20.0) 5.8 (0.5–72.2)
Other 191 36 (18.9) 9.1 (3.8–22.3) 179 35 (19.6) 10.4 (4.0–27.2) 12 1 (8.3) 2.1 (0.1–36.6)
Ever injected drugs, lifetime
Never 1352 38 (2.8) 1.0 1180 31 (2.6) 1.0 172 7 (4.1) 1.0
Ever 879 309 (35.2) 18.8 (13.2–26.6) 825 293 (35.5) 20.4 (13.9–30.0) 54 16 (29.6) 9.9 (3.8–25.8)
OR, odds ratio; CI, confidence interval. Statistically significant associations (p<0.05) are depicted in bold.
3. Results
3.1. Study subjects
Overall 347 of the 2231 participants (15.6%) were HIV-1 sero-
positive at the time of enrollment (Table 1). HIV-1 prevalence
among those who had ever injected (35.2%, N=879) was markedly
higher than among those who had never injected (2.8%, N=1352)
(OR 18.8, 95% CI 13.2–26.6). There was higher sero-prevalence
amongmenas compared towomen (OR1.7, 95%CI 1.1–2.7). Among
male participants, other sociodemographic characteristics statisti-
cally significantly associated with increased risk for HIV infection
included being of Thai ethnicity (compared with ethnic minori-
ties), being between 24 and 34 years old, and having received only
primary school education or less. Men who described themselves
as students or who were married were also at lower risk for HIV
infection. Among female participants, the factors associated with
increased risk of HIV infection were being separated, divorced or
widowed, or having a history of injection drug use.
3.2. HIV subtyping and genetic diversity
Of all the HIV positive individuals in the cohort it was possi-
ble to identify the genotype in 336 (97%) of 347 cases (Table 2).
CRF01 AE was the predominant clade, accounting for over 80% of
the strains. Thirteen specimens (3.9%) were typed as subtype B,
and no sample was typed as subtype C. Inter-subtype recombi-
nants were abundant, accounting for 9.2% of the cases, and were
Table 2
Summary of HIV subtypes of the OUR prevalent cohort.
IDUs Non-IDUs Total
Total no. 309 38 347
Subtyped, n (%) 299 (96.8) 37 (97.4) 336 (96.8)
Pure subtype/CRF
Subtype B, n (%) 12 (4.0) 1 (2.7) 13 (3.9)
Subtype C, n (%) 0 (0.0) 0 (0.0) 0 (0.0)
CRF01 AE, n (%) 243 (81.3) 32 (86.5) 275 (81.8)
Recombinants
B/CRF01 AE, n (%) 27 (9.0) 2 (5.4) 29 (8.6)
C/CRF01 AE, n (%) 1 (0.3) 0 (0.0) 1 (0.3)
B/C n (%) 1 (0.3) 0 (0.0) 1 (0.3)
Dual infections
B/CRF01 AE, n (%) 13 (4.3) 0 (0.0) 13 (3.9)
C/CRF01 AE, n (%) 1 (0.3) 2 (5.4) 3 (0.9)
B/C, n (%) 1 (0.3) 0 (0.0) 1 (0.3)
mostly due to recombinants combining CRF01 AE with subtype
B. Seventeen individuals (5.1%) carried dual infections, predomi-
nantly between subtype B and CRF01 AE; subtype C/CRF01 AE and
subtype B/C co-infections were also recorded, but rarely.
The majority of the HIV infections in the current cohort (84.4%)
were seen among male IDUs. The observed genetic diversity was
evenly distributed among IDUs and non-IDUs, and exhibited no
gender bias. Because of the limited number of HIV-infectedwomen
and non-IDUpatients, we limited the remaining statistical analyses
to IDU men.
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Table 3
Comparison of age, ethnicity, and injection duration across subtype B vs. CRF01 AE, among HIV-infected male IDUs in OUR prevalent cohort.
Variable Subtype/CRF p-Value OR (95% CI)
CRF01 AE, N (%) B, N (%)
Total 231 (100.0) 11 (100.0)
Age (years)
15–34 180 (77.9) 4 (36.4) 0.005* 1.0
35+ 51 (22.1) 7 (63.6) 6.2 (1.7–21.9)
Ethnicity
Thai 158 (68.4) 10 (90.9) 0.18* 1.0
Ethnic minority 73 (31.6) 1 (9.1) 0.2 (0.03–1.7)
Number years been injecting
Less than 6 years 103 (44.6) 1 (9.1) 0.03* 1.0
6+ 128 (55.4) 10 (90.9) 8.1 (1.0–63.9)
* Fisher’s Exact Test two-sided p-value.
3.3. Socio-demographic variables and genetic diversity
Table 3 shows an unadjusted comparison of socio-demographic
and injection factors between the two principal HIV clades,
CRF01 AE and subtype B. Compared to those with CRF01 AE, indi-
viduals with subtype B were more likely to be 35 years of age or
older (OR 6.2, 95% CI 1.7–21.9), and more likely to have injected
drugs for 6 years or more (OR 8.1, 95% CI 1.0–63.9).
An analysis of socio-demographic and behavioral factors asso-
ciated with dual infection is presented in Table 4. In the crude
analysis, individuals with dual infections were more likely to have
an increased frequency of sharing needle/syringe (OR 6.0, 95% CI
1.3–27.1), initiated injecting in the last three years (OR 4.5, 95% CI
1.2–16.7), andhad a lower education level (OR4.2, 95%CI 1.2–15.5).
These associations remained statistically significant after sepa-
rate adjustments for age and for education: increased frequency
of sharing needle/syringe (age-adjusted OR 6.1, 95% CI 1.3–28.3;
education-adjustedOR7.0, 95%CI1.5–34.1), having initiated inject-
ing in the last three years (age-adjusted OR 5.2, 95% CI 1.3–20.8;
education-adjusted OR 3.9, 95% CI 1.1–14.6), and having a lower
educational level (age-adjusted OR 5.2, 95% CI 1.4–20.3).
Those individuals who reported ever having sexual intercourse
were less likely to have a dual infection, although this was not sta-
tistically significant (OR 0.2, 95% CI 0.1–1.2). No other statistical
associations or trends were found between exposure variables and
dual infection.
In a further analysis (data not shown), dual and recombinant
infectionwere combined together as “complex” infection and com-
pared to single clade infections without recombination. Complex
infections were associated with an increased frequency of nee-
dle/syringe sharing (age-adjusted OR 5.3, 95% CI 1.6–17.1).
4. Discussion
In this cohort of drug users in Northern Thailand, we show
that HIV genetic diversity is increasing and is associated with
certainhigh-risk behaviors anddemographic factors. Frequentnee-
dle sharing was associated with both dual and recombinant HIV
infection. Recent injection of drugs and lower education were sig-
nificantly associated with dual HIV infection.
Our findings are consistent with several previous studies that
show increasing HIV genetic diversity in the Thai IDU popula-
tion. In our study, four out of five HIV–1 infections were due to
CRF01 AE. Inter-subtype recombinants outnumbered subtype B
strains. Individuals with subtype B were on average older and had
been injecting drugs longer than those with CRF01 AE, reflecting
the evolution of the HIV epidemic in this population (Tovanabutra
et al., 2004).
Overall, 5.1% (17 of 336) individuals carried dual infections,
a rate substantially higher than has been reported from other
population samples (Hu et al., 2005). This is one of the first IDU
cohorts in which an estimation of the prevalence of dual infec-
tion has been possible and therefore few studies are available
for direct comparison. Of interest, in Thailand a study amongst
126 seroconverting IDUs found, using restriction-fragment length
polymorphism (RFLP) analysis of the HIV protease, that 2/80 indi-
viduals (2.5%) had dual infections in the year following primaryHIV
infection (Hu et al., 2005). By interrogating eight different regions
throughout the HIV genome, the current use of MHAbce may pro-
vide a higher sensitivity for the study of dual infection. Of note,
both RFLP and MHAbce can only detect dual infections when these
are due to different clades but are insensitive to dual infections
with the same clade. The high proportion of dual infections seen
in our cohort of intravenous drug users is biologically plausible.
Injecting the virus into the blood is an efficient mode of HIV trans-
mission, as no mucosal barriers need to be overcome. In addition,
individuals who inject drugs and share needles and other inject-
ing equipment likely have multiple exposures to HIV and other
blood-borne pathogens.
Sexual exposure was not associated with dual infection in this
population. This is likely related to the finding that this is a rela-
tively sexually low risk population with primary HIV acquisition
risks related to injecting practices. Studies among individuals with
multiple and high risk sexual exposure histories (such as sexwork-
ers or persons with other multiple partnership patterns) would be
needed to explore the phenomenonwehave described here among
injectors.
Theprimaryaimof this studywas toassess factors amongst IDUs
associated with increased genetic diversity. The principal finding
was that increased frequency of needle sharing is associated with
much higher rates of dual infection and recombination. Although
mathematical modeling studies have suggested that this may be
an important risk factor (Xiridou et al., 2007), our study is the first
of its nature to demonstrate this empirically. Sharing of needles
is associated with multiple exposures to HIV. This increases the
opportunity of dual infection and recombination, as each expo-
sure facilitates transmissionof differentHIV-1 strains.Other factors
found to be associated with dual infection (recent injection drug
use and low education level) are also likely to be associated with
increased HIV exposure. Sexual risk factors were not associated
with dual or recombinant infection, suggesting it is intravenous
drug use rather than sexual exposure, which is responsible for the
increasing genetic diversity of HIV.
Needle exchange programs have been piloted in Thailand for
some years but widespread implementation has proven difficult
(Kerr et al., 2007). This study shows that such programs could rep-
resent a major intervention to limit the genetic diversity of the
epidemic and should be implemented. Increasing access to sterile
injection equipment (available through pharmacies in Thailand),
providing education on needle hygiene through outreach, and
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Table 4
Crude and age- and education-adjusted odds ratios comparing dual vs. single infection among male IDU.
Variable Total, N Single infectionsa
N (%)
Dual infectionsb
N (%)
Crude OR (95% CI)
(dual vs. single)
Chi-sq p-value Age-adjusted OR
(95% CI)
Education-adjusted
OR (95% CI)
Total HIV+ Male IDUs 283 269 (100.0) 14 (100.0)
Age (years)
15–23 67 63 (23.4) 4 (28.6) 1.4 (0.3–6.4) 0.98*
24–29 84 80 (29.7) 4 (28.6) 1.1 (0.2–5.0)
30–34 64 61 (22.7) 2 (21.4) 1.1 (0.2–5.5)
35+ 68 65 (24.2) 3 (21.4) 1.0
Ethnicity
Thai 198 189 (70.3) 9 (64.3) 1.0
Ethnic minority 85 80 (29.7) 5 (35.7) 1.3 (0.4–4.0) 0.77*
Education level
Primary school or less 136 125 (46.5) 11 (78.6) 4.2 (1.2–15.5) 0.02 5.2 (1.4–20.3)
Secondary school or more 147 144 (53.5) 3 (21.4) 1.0 1.0
Occupation
Unemployed 51 48 (17.8) 3 (21.4) 1.0
Farmer/gardener 72 70 (26.0) 2 (14.3) 0.5 (0.1–2.8)
Other 160 151 (56.1) 9 (64.3) 1.0 (0.6–1.5) 0.70*
Marital status
Ever married 142 133 (49.4) 9 (64.3) 1.0
Never married 141 136 (50.6) 5 (35.7) 0.5 (0.2–1.7) 0.28
Province where currently reside
Chiang Rai 56 54 (20.1) 2 (14.3) 1.0
Chiang Mai 184 173 (64.3) 11 (78.6) 1.7 (0.4–8.0)
Other 43 42 (15.6) 1 (7.1) 0.6 (0.1–7.3) 0.72*
Ever been incarcerated or jailed, lifetime
No 77 73 (27.1) 4 (28.6) 1.0
Yes 206 196 (72.9) 10 (71.4) 0.9 (0.3–3.1) 1.00*
Number of years been injecting
Less than 3 years 57 51 (19.0) 6 (42.9) 4.5 (1.2–16.7) 0.04* 5.2 (1.3–20.8) 3.9 (1.1–14.6)
3–5 68 64 (23.8) 4 (28.6) 2.4 (0.6–9.9) 2.8 (0.6–12.5) 2.4 (0.6–10.1)
6+ 158 154 (57.2) 4 (28.6) 1.0 1.0 1.0
Injected in the past 3 months
No 14 14 (5.2) 0
Yes 269 255 (94.8) 14 (100.0) n/a
Frequency of injecting drugs, past 3 months (n =269)
<Daily 60 57 (22.4) 3 (21.4) 1.0
Daily 209 198 (77.7) 11 (78.6) 1.1 (0.3–3.9) 1.00*
Have you ever shared needle/syringe, lifetime?
No 43 40 (14.9) 3 (21.4) 1.0
Yes 240 229 (85.1) 11 (78.6) 0.6 (0.2–2.4) 0.45*
Have you shared needle/syringe, past 3 months? (n =269)
No 118 113 (44.3) 5 (35.7) 1.0
Yes 151 142 (55.7) 9 (64.3) 1.4 (0.5–4.4) 0.53
Number (on average) of other people shared needle/syringe with, past 3 months (n =151)
One other injector 84 80 (56.3) 4 (44.4) 1.0
2 or more others 67 62 (43.7) 5 (55.6) 1.6 (0.4–6.3) 0.51*
Frequency of sharing needle/syringe with others, past 3 months (n =151)
Half the time or less 137 131 (92.3) 6 (66.7) 1.0 1.0 1.0
More than half the time 14 11 (7.7) 3 (33.3) 6.0 (1.3–27.1) 0.04* 6.1 (1.3–28.2) 7.0 (1.5–34.1)
Ever had sexual intercourse, lifetime
No 12 10 (3.7) 2 (14.3) 1.0
Yes 271 259 (96.3) 12 (85.7) 0.2 (0.1–1.2) 0.11*
Number of sexual partners, lifetime (n =271)
1–9 sexual partners 129 121 (46.7) 8 (66.7) 1.0
10+ 142 138 (53.3) 4 (33.3) 0.4 (0.1–1.5) 0.18
Ever had sex with a female sex worker, lifetime (n =271)
No 80 78 (30.1) 2 (16.7) 1.0
Yes 191 181 (69.9) 10 (83.3) 2.2 (0.5–10.1) 0.52*
Ever had sex with another man, lifetime (n =271)
No 252 240 (92.7) 12 (100.0)
Yes 19 19 (7.3) 0 n/a
Any lab-diagnosed STD (Syphillis, Chlamydia and/or Gonorrhea) (n =271)
No 255 243 (93.8) 12 (100.0)
Yes 16 16 (6.2) 0 n/a
a Single infection=CRF01 AE, subtype B, subtype C, B/CRF01 AE Recombinant, C/CRF01 AE Recombinant, or B/C Recombinant.
b Dual infection=B/CRF01 AE Dual, C/CRF01 AE Dual, or B/C Dual.
* Fisher’s Exact Test two-sided p-value.
increasing access to drug treatment services will all be helpful
in reducing harm associated with HIV acquisition and transmis-
sion.
As found in other studies we found significantly lower rates of
HIV infection among drug users who reported never had injected
drugs (Beyrer et al., 2004). While increased sexual risk-taking has
been associated with HIV acquisition among non-injecting drug
users in other settings, we found very low rates of HIV among
these cohort participants, most of whom were methamphetamine
smokers.
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Dual infection and recombination are major concerns for future
vaccine design. Fortunately, current vaccine candidates contain
both subtype B and CRF01 AE, and could potentially protect against
recombinant strains of the parent viruses. However, such vaccines
candidates may not be able to protect against other recombinants
(McKinnon et al., 2005; Taylor et al., 2008). A further challenge is
that dual HIV infection may increase disease progression (Gottlieb
et al., 2004). Recombination may also lead to the development of
more difficult to treat variants, as demonstrated by a recent case in
the United States (Blick et al., 2007).
There were several limitations to this study. First, the cross-
sectional nature of the studymeans causality could not be assessed.
Therefore it was not possible to elucidate if acquisition of HIV
occurred prior to exposure to social risk factors or vice versa. Sec-
ond, all informationonbehavioral risk factorswere fromself-report
and therefore may not be accurate. Third, it was not possible to
obtain the subtypeofpatients for11 (3.2%)of the studyparticipants,
which could have introduced modest selection bias into the study.
However these individuals did not differ significantly in exposure
variables to those who were included in the subtype analysis (data
not shown). Although theoverall cohortwas large, the total number
of individualswhohaddual or recombinant infectionwas relatively
small. Asa result itwasnotpossible toanalyzedifferencesof genetic
diversity between sexes, and in the non-IDU population. Finally,
the specimens analyzedwere from an earlier phase of the Thai epi-
demic, and may not reflect the current molecular epidemiology of
HIV in this population.
In conclusion, to limit the increasing and expanding com-
plexity of HIV-1 strains in Thailand early intervention should
be aimed at reduction in needle sharing, especially among new
IDUs. These results highlight how molecular epidemiology can
identify those risks most likely to increase the complexity of
strains, and so assist with targeting interventions to limit HIV
diversity.
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